Bispecific T-cell engagers in oral cancer immunotherapy

• The development of BiTEs has revolutionized the way we treat oral cancer. These treatments precisely target malignant cells by linking T cells to tumor cells, allowing the body's defenses to launch an attack against them. Better treatment outcomes and more promising futures for patients are promised by this. • Our ability to combat cancers is significantly increased when we mix immune-twisting medications, such as immunological checkpoint inhibitors or conventional chemotherapy, with BiTE therapy. This customized method gives patients hope, particularly for solid tumors, as it customizes therapy to meet their individual needs. • Better cancer treatments are getting closer as long as we continue to investigate novel targets and improve the architecture of BiTEs. BiTE therapy is poised to revolutionize the way we treat oral cancer thanks to continued research and testing. It's a positive development for individualized cancer care and a ray of hope for people receiving difficult diagnoses.